These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15576286)

  • 41. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The application of human phase 0 microdosing trials: A systematic review and perspectives.
    Svendsen P; El-Galaly TC; Dybkær K; Bøgsted M; Laursen MB; Schmitz A; Jensen P; Johnsen HE
    Leuk Lymphoma; 2016; 57(6):1281-90. PubMed ID: 26428262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
    Mandal R; Sawyer MB; Li XF
    Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The (ir)relevance of plasma protein binding of anticancer drugs.
    Sparreboom A; Nooter K; Loos WJ; Verweij J
    Neth J Med; 2001 Oct; 59(4):196-207. PubMed ID: 11578795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antineoplastic drug monitoring.
    Henner WD
    Clin Lab Med; 1987 Sep; 7(3):625-39. PubMed ID: 3308299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Kim HJ; Seo KA; Kim HM; Jeong ES; Ghim JL; Lee SH; Lee YM; Kim DH; Shin JG
    J Pharm Biomed Anal; 2015 Jan; 102():9-16. PubMed ID: 25218029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An automated method for supporting busulfan therapeutic drug monitoring.
    Juenke JM; Miller KA; McMillin GA; Johnson-Davis KL
    Ther Drug Monit; 2011 Jun; 33(3):315-20. PubMed ID: 21544019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients.
    Laverdière I; Caron P; Couture F; Lévesque E; Guillemette C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 885-886():131-7. PubMed ID: 22265668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liquid chromatography-tandem mass spectrometry method as the golden standard for therapeutic drug monitoring in renal transplant.
    Aucella F; Lauriola V; Vecchione G; Tiscia GL; Grandone E
    J Pharm Biomed Anal; 2013 Dec; 86():123-6. PubMed ID: 23995754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic drug monitoring opportunities in cancer therapy.
    McLeod HL
    Pharmacol Ther; 1997; 74(1):39-54. PubMed ID: 9336015
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using metabolomics to monitor anticancer drugs.
    Chung YL; Griffiths JR
    Ernst Schering Found Symp Proc; 2007; (4):55-78. PubMed ID: 18811053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic drug monitoring in neonates: problems and issues.
    Gal P
    Drug Intell Clin Pharm; 1988 Apr; 22(4):317-23. PubMed ID: 3286175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic drug monitoring in clinical toxicology: current strategies, thoughts and views on the future.
    Lambert W; Neels H
    Clin Chem Lab Med; 2004; 42(11):1203. PubMed ID: 15576283
    [No Abstract]   [Full Text] [Related]  

  • 55. Antineoplastic drugs and their analysis: a state of the art review.
    Guichard N; Guillarme D; Bonnabry P; Fleury-Souverain S
    Analyst; 2017 Jul; 142(13):2273-2321. PubMed ID: 28560370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroleptic drug levels in erythrocytes and in plasma: implications for therapeutic drug monitoring.
    Garver DL
    Psychopharmacol Ser; 1989; 7():244-56. PubMed ID: 2574450
    [No Abstract]   [Full Text] [Related]  

  • 57. Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015)　- Digest Version.
    Aonuma K; Shiga T; Atarashi H; Doki K; Echizen H; Hagiwara N; Hasegawa J; Hayashi H; Hirao K; Ichida F; Ikeda T; Maeda Y; Matsumoto N; Sakaeda T; Shimizu W; Sugawara M; Totsuka K; Tsuchishita Y; Ueno K; Watanabe E; Hashiguchi M; Hirata S; Kasai H; Matsumoto Y; Nogami A; Sekiguchi Y; Shinohara T; Sugiyama A; Sumitomo N; Suzuki A; Takahashi N; Yukawa E; Homma M; Horie M; Inoue H; Ito H; Miura T; Ohe T; Shinozaki K; Tanaka K;
    Circ J; 2017 Mar; 81(4):581-612. PubMed ID: 28302953
    [No Abstract]   [Full Text] [Related]  

  • 58. Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream.
    Di W; Tan X; Calderon IAC; Neal Reilly AE; Niedre M; Clark HA
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3509-3517. PubMed ID: 32019879
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of age on the distribution of drug in blood.
    Kitazawa S; Maeda A
    Chem Pharm Bull (Tokyo); 1976 Dec; 24(12):2961-8. PubMed ID: 1022342
    [No Abstract]   [Full Text] [Related]  

  • 60. ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements.
    Reynolds DJ; Aronson JK
    BMJ; 1993 Jan; 306(6869):48-51. PubMed ID: 8435581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.